Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 18/20 | 0.71 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | NQO1 | P15559 | 4/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753153 | 0.95 | NQO2 (0.66) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13916795 | 0.95 | NQO2 (0.68) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13916807 | 0.92 | NQO2 (0.64) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL753152 | 0.89 | NQO2 (0.61) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL6503570 | 0.89 | NQO2 (0.58) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL6502756 | 0.87 | NQO2 (0.56) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13928512 | 0.86 | NQO2 (0.76) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL7062442 | 0.83 | NQO2 (0.52) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL6508268 | 0.83 | NQO2 (0.51) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13668821 | 0.82 | NQO2 (0.53) | NQO2SMARCA2NSD2NQO1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541483-B2 | Bisimidazoacridones, bistriazoloacridones and hybrids having both moieties; HIV | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-04-01 | — | — | US | disclosed |
| EP-0892801-B1 | ACRIDONE-DERIVED COMPOUNDS USEFUL AS ANTINEOPLASTIC AND ANTIRETROVIRAL AGENTS | US GOV HEALTH & HUMAN SERV (US) | 2002-01-02 | — | — | EP | disclosed |
| US-20010009914-A1 | Acridone-derived compounds useful as antineoplastic and antiretroviral agents | MICHEJDA CHRISTOPHER J (US) | 2001-07-26 | — | — | US | disclosed |
| US-6187775-B1 | Acridone-derived compounds useful as antineoplastic and antiretroviral agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009914-A1 | Acridone-derived compounds useful as antineoplastic and antiretroviral agents | EIF2AK2, SAMHD1, ZC3HAV1 | NQO2 1478/4885SMARCA2 3331/4885NSD2 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.